Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint
Inhibitor Therapy / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 534-540, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-939743
ABSTRACT
Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Inhibidores de Puntos de Control Inmunológico
/
Inmunoterapia
/
Neoplasias Pulmonares
/
Neoplasias
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS